Safety Alerts & Recalls

Search all Safety Alerts & Recalls

Latest Alerts

Puren Pharma ruft alle Chargen von Moxonidin-Actavis 0,3 mg und 0,4 mg Filmtabletten zurück
Die Firma Puren Pharma GmbH & Co. KG ruft alle Chargen Moxonidin-Actavis 0,3 mg und Moxonidin-Actavis 0,4 mg Filmtabletten, jeweils Packungen mit 100 Stück, vom Markt zurück. Die Medikamente werden zurückgerufen, weil die Zulassung für diese Medikamente am 01 Januar 2018 erloschen ist und sie nach diesem Datum nicht mehr verkauft werden dürfen. Moxonidin-Actavis 0,3 mg und Moxonidin-Actavis 0,4 mg Filmtabletten werden zur Behandlung von hohem Blutdruck (Hypertonie) eingesetzt. Dieser Rückruf betrifft nur Moxonidin-Actavis 0,3 mg und Moxonidin-Actavis 0,4 mg Filmtabletten. Keine anderen Stärken und keine Moxonidin-Präparate anderer Hersteller sind von dem Rückruf betroffen. Weitere Informationen finden Sie unter: http://www.drugbase.de/de/datenbanken/abda-datenbank/aktuelle-infos/artikel.html?tx_ttnews%5Btt_news%5D=2178002&tx_ttnews%5BbackPid%5D=115&cHash=a8e4f4b46a26226747cd17b58926cdb1
Learn More

Strathclyde Pharmaceuticals Ltd recalls single batch of Xarelto 20mg film-coated tablets after reports of rogue blister strips of 15 mg tablets within packs of 20 mg tablets
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued an alert advising the recall of one batch of Xarelto (Rivaroxaban) 20mg tablets. The affected batch number is BXHHDR1 with expiry date 09/2019, and it was first distributed on 18/09/2017. This follows reports to the manufacturers, Strathclyde Pharmaceuticals Ltd, of a rogue blister strip of 15 mg tablets being found within two packs of 20 mg tablets. As a result, they have decided to recall the entire batch. Xarelto, which contains the medication Rivaroxaban, thins the blood and is used to prevent blood clots and lower the risk of stroke. For more information and for a comprehensive list of batch numbers affected, please visit: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-xarelto-20-mg-film-coated-tablets-rivaroxaban
Learn More

Date Published Title Medicine Source
2018-01-02 Puren Pharma ruft alle Chargen von Moxonidin-Actavis 0,3 mg und 0,4 mg Filmtabletten zurück Moxonidine AMK
2017-12-08 Strathclyde Pharmaceuticals Ltd recalls single batch of Xarelto 20mg film-coated tablets after reports of rogue blister strips of 15 mg tablets within packs of 20 mg tablets MHRA
2017-12-08 Healthcare Professionals Advised of Serious Cardiac-Related Adverse Reactions with High Doses of Loperamide Loperamide MHRA
2017-12-08 Healthcare Professionals Advised of the Contraindication of Daktarin oral gel in Patients Taking Warfarin Warfarin MHRA
2017-12-08 Healthcare Professionals Advised of the Risk of Severe Respiratory Depression with Gabapentin Gabapentin MHRA
2017-12-08 Pfizer Recalls Batches of Atorvastatin and Lipitor Due to Potential of Out of Specification Result for Microbiological Testing Atorvastatin MHRA
2017-12-08 Takeda Recalls One Batch of Calcichew-D3 caplets due to non-approved excipient being found Calcium MHRA
2017-12-08 Healthcare Professionals Advised of Dose-Dependent QT-Prolonging Effects of Quinine and Updated Medicine Interactions Quinine Sulphate MHRA
2017-12-08 Healthcare Professionals Reminded to Prescribe and Dispense Tacrolimus by Brand Name Only Tacrolimus MHRA
2016-07-06 Teva Pharmaceuticals USA Recalls Single Lot of Nabumetone 750 mg Tablets Nabumetone FDA
2016-02-03 Los Profesionales Sanitarios Informados: Viekirax (Ombitasvir, Paritaprevir, Ritonavir) No Recomendado En Pacientes Con Determinados Problemas En El Hígado AEMPS
2015-05-28 RelonChem Recalls All Unexpired Tramadol 50mg Capsules Over Fungal Contamination Risk Tramadol MHRA
2015-02-19 Healthcare Professionals Advised of New Law that Sets Blood Concentration Limits for Certain Drugs When Driving Methadone MHRA
2015-02-19 MHRA Advises Healthcare Professionals that Spiriva Respimat and Handihaler Have Similar Benefits and Risks Tiotropium MHRA
2015-02-19 Clinigen Advises Healthcare Professionals About Vibativ Safety Concerns MHRA
2015-02-19 Healthcare Professionals Advised Not to Use Erivedge in Women of Childbearing Potential MHRA
2015-02-17 MHRA Advises Lowest Effective Dose of HRT Should Be Used for Shortest Possible Time Ethinylestradiol MHRA
2014-11-12 Glaxo SmithKline Recalls Zovirax Eye Ointment Over Impurities Aciclovir MHRA
2014-09-05 Motilium No Longer Available Over the Counter Without a Prescription Domperidone MHRA
2014-07-02 Procoralan Linked to Potential Risk of Heart Attack and Stroke in Patients with Slow Heart Beat Ivabradine MHRA